Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Not applicableNot Yet RecruitingNCT07764744
What this trial is testing

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Who this might be right for
Ovarian NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation+2 more
Weill Medical College of Cornell University 70
Testing effectiveness (Phase 2)Study completedNCT03205761
What this trial is testing

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 11
Not applicableLooking for participantsNCT06111417
What this trial is testing

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners

Who this might be right for
Breast Cancer
Centre Georges Francois Leclerc 150
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07652073
What this trial is testing

DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Who this might be right for
Advanced or Metastatic Ovarian Cancer
Danatlas Pharmaceuticals Co., Ltd 30
Not applicableStudy completedNCT00165152
What this trial is testing

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Who this might be right for
Breast CancerOvarian Cancer
Dana-Farber Cancer Institute 150
Early research (Phase 1)Study completedNCT01237067
What this trial is testing

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Who this might be right for
Ovarian CancerBreast CancerPrimary Peritoneal Cancer+2 more
National Cancer Institute (NCI) 77
Early research (Phase 1)Active Not RecruitingNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Varun Monga, MBBS 13
Not applicableStudy completedNCT05305001
What this trial is testing

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Who this might be right for
Pancreatic CancerPancreatic Adenocarcinoma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Testing effectiveness (Phase 2)Study completedNCT04089189
What this trial is testing

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Who this might be right for
Ovarian Cancer
Impact Therapeutics, Inc. 93
Not applicableStudy completedNCT00579007
What this trial is testing

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

Who this might be right for
Breast CancerOvarian Cancer
Memorial Sloan Kettering Cancer Center 224
Large-scale testing (Phase 3)Study completedNCT03106987
What this trial is testing

Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

Who this might be right for
Epithelial Ovarian Cancer
AstraZeneca 220
Not applicableUnknownNCT05857670
What this trial is testing

Psyco Quality of Life and Procreation BRCA1/2

Who this might be right for
Breast CancerGenetic Predisposition
Regina Elena Cancer Institute 200
Not applicableStudy completedNCT06534424
What this trial is testing

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Who this might be right for
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Ohio State University Comprehensive Cancer Center 152
Not applicableStudy completedNCT00858078
What this trial is testing

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

Who this might be right for
BRCA1 GeneBRCA2 Gene
National Cancer Institute (NCI) 76
Not applicableUnknownNCT02593435
What this trial is testing

The Registration Program of BRCA1/2 Gene

Who this might be right for
Breast Cancer
Chinese Anti-Cancer Association 8,000
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)UnknownNCT05327621
What this trial is testing

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 50
Next Page